Approval of the first medications targeting NASH patients

16 Mar 2017

Topics: Drug review |

Provided by Datamonitor Healthcare: data analysis and insight |

With the upcoming approval of the first medications targeting NASH (non-alcoholic steatohepatitis) patients, the market value is predicted to reach over US$7.5bn by 2025. Our latest infographic reveals more information about the current drugs in development and the estimated increase in sales that will occur over the next few years.

Since there are currently no approved medications for the treatment of NASH, the first medications that are approved will be highly sought after in the industry.
See at a glance:

See how much the US market will account for in terms of NASH patients and NASH sales by 2025
See the predicted 2025 NASH sales by country (UK, USA, SPAIN, Germany, France, Italy) The
See the expected uptake of the pipeline medications

Gain more insights on the market by downloading your complimentary infographic on Non-alcoholic steatohepatitis (NASH) today